Schizophrenic Disorders Clinical Trial
Official title:
Study on the Links Between Perception and Action in Schizophrenia, "Upside Down, Give me the Handle"
In schizophrenia, dislocation of psychic functions involving a loss of contact with reality is frequently found. A fragmentation of motor and sensory perceptions could be held responsible (Fuchs, 2005). However, automatic integration between perception and action is the necessary condition to be in "relationship with the world." Affordance is the experimental link between object perception and actions potentially associated (Gibson (1977, 1979) explored by Stimulus Response Compatibility (SRC) paradigm. The existence of visual motor neurons leads us to postulate that the affordance effect can be assisted by a visuomotor priming of a hand in a position to grasp. With Tucker & Ellis sensory motor compatibility task, we study the capacity of affordance in schizophrenia, as well as the impact of perceptual motor priming on these affordance effects.
All participants will perform cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987). Controls will only have the first three tasks (cognitive spots Alert and laterality). Then all will perform all tasks in successive order (task 1 and task 2). For both tasks, photographs of 20 objects of everyday life typical grip with one hand are presented in 4 orientations. The instruction is to say if the object is presented upright or inverted; The second task differs from the first only by the introduction of a prime: presenting a hand in position "catching" before the picture of an object ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04608032 -
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
|
N/A | |
Terminated |
NCT00660595 -
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
|
Phase 3 | |
Completed |
NCT02655172 -
Have a Good Grasp of the Worldthe World
|
N/A | |
Completed |
NCT01606436 -
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
|
Phase 1 | |
Completed |
NCT01729650 -
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
|
N/A | |
Completed |
NCT02525315 -
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations
|
Phase 2 | |
Completed |
NCT00488319 -
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
|
Phase 3 | |
Completed |
NCT00088491 -
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
|
Phase 3 | |
Completed |
NCT01279213 -
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
|
Phase 4 | |
Completed |
NCT00600756 -
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
|
Phase 3 | |
Completed |
NCT00572247 -
The Psychiatric Rehabilitation Approach to Weight Loss
|
N/A | |
Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
Completed |
NCT00485823 -
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
|
Phase 4 | |
Active, not recruiting |
NCT00161408 -
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
|
N/A | |
Terminated |
NCT05164289 -
Interest of EMDR Schizophrenic Disorders
|
||
Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
Completed |
NCT00088465 -
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
Withdrawn |
NCT02654405 -
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 |